CD4%20for%20monitoring%20HIV%20Progression - PowerPoint PPT Presentation

About This Presentation
Title:

CD4%20for%20monitoring%20HIV%20Progression

Description:

Indian Association of Preventive & Social Medicine, ... Coulter manual. FACSCount. System. Pharmas taking action. Abbott Laboratories. Bristol-Meyers Squibb ... – PowerPoint PPT presentation

Number of Views:264
Avg rating:3.0/5.0
Slides: 42
Provided by: sin51
Category:

less

Transcript and Presenter's Notes

Title: CD4%20for%20monitoring%20HIV%20Progression


1
CD4 for monitoring HIV Progression
  • 31st Annual National Conference of
  • Indian Association of Preventive Social
    Medicine,
  • 27th 29th Feb 2004
  • PGIMER, Chandigarh
  • Dr. Arvinder Singh
  • BD Biosciences

2
BD Activities
Brazil -COOPEX -MOH -BDB
3
HIV/AIDSWhat is CD4/CD8
4
(No Transcript)
5
(No Transcript)
6
Flow Cytometry Clinical Applications
  • HIV immunophenotyping (CD4 absolute counts)
  • Cytokine analysis
  • Leukemia and lymphoma diagnosis - minimum
    residual disease detection
  • Cell cycle and DNA ploidy analysis
  • Stem Cell Analysis
  • HLA B 27 Typing
  • Residual white blood cell detection
  • Reticulocyte enumeration
  • Flow crossmatching (organ transplantation)

7
What Is Flow Cytometry?
  • A technology that simultaneously measures
    multiple characteristics of single cells at a
    rapid rate

8
(No Transcript)
9
Lysed Whole Blood
Neutrophils
Side Scatter
Monocytes
Lymphocytes
Forward Light Scatter
10
(No Transcript)
11
(No Transcript)
12
Two-Color Cell Analysis
10 4
10 3
CD8 PE
10 2
10 1
10 0
10 0
10 1
10 2
10 3
10 4
CD4 FITC
13
(No Transcript)
14
Four color analysis
CD8 PE
SSC Height
CD45 PerCP
CD3 FITC
CD8 PE
CD4 Cy5
CD3 FITC
CD4 Cy5
15
42 Million People Living with AIDS
16
India Current Situation HIV
  • HIV prevalence rate is 0.7
  • India has had a sharp increase in the estimated
    number of HIV infections, from a few thousand in
    the early 1990s to a working estimate of about
    3.8 million children and adults living with
    HIV/AIDS in 2001
  • Estimates range from 8 - 15 million HIV infected
    adults and children living with HIV in 2010
  • Given India's large population, a mere 0.1
    percent increase in the prevalence rate would
    increase the number of adults living with
    HIV/AIDS by over half a million people

17
India Current Situation HIV
  • About 90 of the total reported AIDS cases occur
    in the sexually active and economically
    productive 15 to 44 age group
  • Men account for 79 of HIV infections in India
  • The predominant mode of HIV transmission is
    through heterosexual contact
  • In 2001, the HIV infection rate went above one
    per cent in six states
  • Maharashtra, Tamil Nadu and Manipur - account for
    75 of estimated HIV cases
  • the burden of AIDS cases is beginning to be felt
    in states affected early - Mumbai and Manipur
    have recorded 20 to 49 per cent bed occupancy by
    HIV positive people in certain hospitals

18
HIV/AIDS Pandemic
  • Disease Management
  • Vaccines, Drugs, Education
  • Antiretroviral Therapy (ART)
  • Controls disease progression
  • Increasing drug resistance patterns
  • Expensive (Big Pharma western countries)
  • Trend to affordable (generic) drugs in
    developing world
  •  
  • CD4 T-Lymphocyte Count
  •   Flow cytometry is gold standard
  • Alternate technologies currently inadequate
  • FacsCount is considered system of choice
  • CD4 count is the single most important
    objective criteria to guide clinical
    decision-making on when to use ART

19
HIV Testing paradigm
Screen
Confirm
CD4
Viral load
Est. annual tests
15-20M
1-2M
4-6M
5-8M
(includes genotyping)
20
PCR Viral load
  • It is a technique that imitates a cells
    ability to replicate DNA by generating multiple
    copies of specific sequences of DNA through
    amplification. In clinical diagnostics, a
    specimen of genetic material can be repeatedly
    copied by PCR to provide sufficient material to
    detect the presence or absence of a virus as well
    as to quantitate its levels in the blood. Its
    used for
  • The development of new drugs
  • To establish a patients disease status and the
    likelihood of disease progression
  • To determine when to start treatment
  • To help the physician decide which drugs to use
    in a treatment regimen
  • To assess whether a treatment regimen is working

21
CD4 and viral load
22
HIV/AIDS Pandemic
  • Situational Analysis
  • Unmet Needs
  •   Affordable drugs/ART
  •   Affordable CD4

23
Flow Cytometry
  • GOLD STANDARD FOR CD4/CD8
  • Monitoring in HIV/AIDS Patients
  • Conceptually established by BD Worldwide

24
FACSCount - Complete SystemIVD approved ( US FDA
)
25
FACSCount - Complete System
Premeasured Reagents
26
FACSCount - Complete System
FACSCount Reagents and Controls
FACSCount Workstation
27
FACSCount
Measuring Absolute CD4, CD8 and CD3 Counts In
Three Easy Steps
28
FACSCount - Clinical Need
  • Safety
  • Minimal Sample Preparation
  • Fixed Samples
  • Absolute Counts
  • Limited Handling of
  • Biohazardous Samples

29
FACSCount - Clinical Need
  • Easy to use
  • Absolute Counts
  • Unit Dose Reagents
  • Minimal Hands-On Time
  • No Formal Training Required

30
FACSCounts in India
  • 35 Placements
  • 23 Instruments through NACO
  • 12 Instruments in Private Path
    Laboratories

31
Reference Range of Lymphocytes Subsets In Healthy
Individuals (India)
  • MALES
  • CD3 617 2485
  • CD19 125 701
  • CD4 337 1090
  • CD8 174 1240
  • Ratio 0.61 2.68
  • HIV Patients-Low CD4
  • FEMALES
  • CD3 898 2786
  • CD19 119 721
  • CD4 424 1050
  • CD8 255 1353
  • Ratio 0.95 2.40

32
FACSCount - Analysis
  • A hard copy results
  • The control
  • Patient sample

33
HIV Monitoring
BD provides a gold standard system of reliable
products and support services for CD4 T-cell
testing at affordable pricing.
  • Appropriate Technology
  • Flow Cytometry
  • Capacity Building
  • Training, Support, Service
  • Reliable Laboratory Systems
  • GMP/GLP (IVDP)/GCP

34
Performance of Competitive Tests
System Correlation w/FCM
FACSCount . 98
Coulter manual .74-.91
Zymmune .92-.94
Capcellia NA
Dynabeads .94
Viral Load N/A

35
Pharmas taking action
  • Abbott Laboratories
  • Bristol-Meyers Squibb
  • GlaxoSmithKline
  • Hoffmann La-Roche Ltd
  • Boehringer Ingelheim
  • Merck Co., Inc
  • Pfizer
  • Cipla
  • Ranbaxy
  • Matrix

36
  • General concensus is that flow cytometry based
    CD4 count is the most accepted technique to HIV
    monitoring
  • Quantitative more cells counted, more reliable
    result
  • Specific mAb, identify CD4 T-lymphocytes most
    precisely
  • QA/QC internal and external - necessary for
    accreditation
  • Throughput manual operation is acceptable as
    technician costs are not significant and does not
    limit test demand
  • Existing flow cytometry systems (FACSCalibur or
    similar) are adequate/accepted for Central
    Reference facilities usually at the sites of
    principal government services
  • Perform broad clinical testing plus Research
    studies associated with international partners
  • Affordable lower cost platform required at
    Provincial and Local clinic sites dedicated
    clinical test platform
  • Capability to perform CD4 count ( - ideal with
    broader test menu )
  • Current FACSCount system should be viewed as
    maximal technology complexity sample
    preparation potential issue reagent cost
    limitation
  • Challenge from Partec / Guava like technology or
    alternative assays

37
Application Comparison
BD TriTest Three Colour Leucogating Two Colour
Monoclonal Ab panel CD3/CD4/CD45 CD45/CD4
Type of Platform Dual/Single Dual/Single
Type of Assay Lyse no Wash Lyse Wash
Isotype controls No Isotype Control No Isotype Control
Gating strategy CD45/SS (heterogeneous) Expert lymphocyte auto-gating software CD45/SS (heterogeneous)
Advantage CD3 is an additional lineage marker for T-lymphocytes increasing the confidence level on defining CD4 T-cells
Cell Type Enumeration CD3 T-cells, CD4 T-cells, (absolute and of CD45) CD4 T-cells (absolute and of CD45)
Analysis Automated with MultiSet software Manual

38
Affordable Testing for HIV/AIDS in the Developing
WorldFebruary 5, 2004 On January 14, 2004, the
William J. Clinton Presidential Foundation
announced that BD, through BD Biosciences, had
entered into an agreement with the Foundation to
provide affordable CD4 testing, both reagents and
instruments, to the poorest and most severely
HIV/AIDS afflicted areas in the developing world.
The CD4 immunocytometry test has been used to
establish decision points for antiretroviral
(ARV) therapy, to monitor efficacy of various
treatments, as a prognostic indicator, and as one
criterion for initiating prophylaxis for
opportunistic infections. The viral load test
helps measure how effective ARV therapies are in
suppressing the virus and can alert clinicians
about the need to adjust dosages or change
regimens.
39
BD BiosciencesAccomplishing our Mission
HIV/AIDS
  • BD Biosciences is Helping With the Global AIDS
    Crisis by
  • Supporting the Brazilian AIDS prevention program
  • Example program for reducing mortality and new
    infections in the developing world
  • Our flow instruments and reagents are used as the
    gold standard to monitor disease progression in
    HIV-infected individuals
  • Collaborating with the International AIDS Vaccine
    Initiative (IAVI)
  • Speed the development and distribution of
    preventive AIDS vaccines
  • Our flow instruments and reagents are used to
    detect immune response to the vaccine

40
HIV/AIDS
PANDEMIC
  • 2010
  • 80 million PLWHA
  • India (15 million) China (15 million)
  • Negative growth rates in most of Africa due to
    AIDS mortality
  • WW economic impact
  •  
  • 2002
  • Brazil
  • Achieves 50 reduction in AIDS deaths over last
    10 years
  • Accessible drugs and health care
  • 500,000 million savings on AIDS impact

41
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com